Researchers are looking for new treatments for people living with HIV-1(Human Immunodeficiency Virus Type 1). HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. HIV-1 treatments, called ART (antiretroviral therapy), involve taking medicines to lower the amount of HIV-1 virus in the body. Standard ART may include Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) and Dolutegravir (DTG). MK-4646 is a trial medicine designed to treat HIV-1. Before giving a trial medicine to people with a health condition, researchers first do trials in healthy people. The goals of this study are to learn: * If taking MK 4646 together with BIC/FTC/TAF or DTG changes the amount of these ARTs in the blood over time. * About the safety of MK-4646 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) of Bictegravir
Timeframe: At designated timepoints (up to approximately 72 hours post dose)
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) of Emtricitabine
Timeframe: At designated timepoints (up to approximately 72 hours post dose)
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) of Tenofovir Alafenamide
Timeframe: At designated timepoints (up to approximately 72 hours post dose)
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) of Tenofovir
Timeframe: At designated timepoints (up to approximately 72 hours post dose)
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-∞) of Dolutegravir
Timeframe: At designated timepoints (up to approximately 72 hours post dose)